

Arritmias no pós operatório de TGA

Rogério Andalaft
Faculty PALS
American Heart Association



Seção Médica de Eletrofisiologia Clínica e Arritmias Cardíacas
Instituto Dante Pazzanese de Cardiologia



Arritmias

The diagram features a central green double-headed arrow connecting the top red box to the bottom-left green box, and a black double-headed arrow connecting the top red box to the bottom-right yellow box. An orange double-headed arrow is also present, connecting the bottom-left green box to the bottom-right yellow box. The background includes a faint circular seal with the text 'INSTITUTO DE CARDIOLOGIA DO ESTADO DE SÃO PAULO' and a central emblem.

***Cardiopatias
simples***

***Cardiopatias
complexas***

Gatilhos


The diagram illustrates the relationship between three factors: Triggers (Gatilhos), Substrate (Substrato), and Modulating Factors (Fatores moduladores). Triggers are at the top in a red box. Substrate is at the bottom left in an orange box. Modulating Factors are at the bottom right in a yellow box. An orange double-headed arrow connects Triggers and Substrate. A black double-headed arrow connects Triggers and Modulating Factors. A green double-headed arrow connects Substrate and Modulating Factors. The background features a faint watermark of the Instituto de Cardiologia do Estado de São Paulo seal.

Substrato

***Fatores
moduladores***


Distribuição das arritmias n= 462815 exames

Presença de arritmias supraventriculares ou ventriculares




Sexo masculino 178513 exames
Sexo feminino 284302 exames

Arritmias SV ou V




Distribuição das arritmias atriais


n= 462815 exames



Identificação dos eventos arrítmicos



Identificação dos eventos arrítmicos



Cirurgias

Manipulação atrial
ou valvar
tricuspid ou mitral

Manipulação ventricular
ou ampliação valvar
aórtica ou pulmonar

Isomerismos

Disfunção sinusal
Ritmo atrial ectópico
Taqui reentrada


Taquicardias
juncionais

Taquicardias
ventriculares

Bloqueios AV



“As arritmias são os gritos de um coração doente”



• CEC

• Distúrbios metabólicos

• Stress catecolaminérgico

Arritmias atriais

Disfunção sinusal

• DVA

Arritmias

Taquicardias

Bradicardias



TSV


Ventriculares

Automatismo

Bloqueios sinoatriais


Bloqueios AV






Abordagem cirúrgica nos pacientes portadores de arritmia (n=93)

Abordagem cirúrgica




Eventos arritmicos consecutivos (124) em 93 pacientes portadores de arritmias

Número de eventos consecutivos




Cardiopatias mais propensas à arritmia




Índice de mortalidade após TSV


Evolução pós arritmia supraventricular




Resultados – Incidência de eventos arrítmicos




Distribuição dos eventos arrítmicos



Distribuição dos eventos arrítmicos



Taquicardia juncional



- Onda P pode vir antes, durante ou após o QRS
- Discordância entre P e QRS
- **Arritmia automática frequente no Pós operatório de cirurgias com manipulação ventricular e da junção (ex ventriculoseptoplastia)**
- Por vezes necessitam de drogas que controlem o automatismo
- Por vezes diagnóstico difícil
 - Utilidade de fio atrial ou eletrodo esofágico

T

Diagnóstico não confirmado

I

aVR

V1

V4

II

aVL

V2

V5


III

aVF

V3

V6

II



Equip:

Veloc: 25 mm/s

Membro: 10 mm/mV Tórax: 10 mm/mV


F 60~ 0,15-150 Hz

PH080A

P?

T 23

Diagnóstico não confirmado



Equip:

Veloc: 25 mm/s

Membro: 10 mm/mV Tórax: 10 mm/mV

F 60~ 0,15-150 Hz

PH080A

P?

Postoperative Junctional Ectopic Tachycardia

General measures

- Adequate sedation
- Normalize electrolytes
- Decrease inotropes
- Cooling

Attempt AAI / AOO pacing

If unsure of diagnosis:
atrial ECG, adenosine

IV Amiodarone bolus

- 1 mg/kg over 10 mins
- Max: 5 mg/kg over 60 mins
- Assess efficacy every 10 mins

"efficacy" = NSR or slow
enough JET to pace at
acceptable rate

Very good

Good-fair

None

Discontinue further IV
Amiodarone boluses

IV Amiodarone infusion

- 5 mcg/kg/minute
- Max: 10 mcg/kg/minute
- Assess efficacy

Good-fair

None


Temporary pace
(A Pace V sense mode)

- Dexmedetomidine 1 mcg/kg load, 1 mcg/kg/hour infusion
- Magnesium 25-50 mg/kg over 10 minutes
- Procainamide 7-10 mg/kg over 30-45 minutes, 40-60 mcg/kg/minute infusion; levels at 4 hours
- Esmolol 50-300 mcg/kg/minute infusion after load
- Assess efficacy after each step

None

Consider extracorporeal
membrane oxygenation, ablation

Identificação dos eventos arrítmicos








Changes in Hospitalization Patterns Among Patients With Congenital Heart Disease During the Transition From Adolescence to Adulthood



Seção Médica de Eletrofisiologia Clínica e Arritmias Cardíacas
Instituto Dante Pazzanese de Cardiologia




(J Am Coll Cardiol 2007;49:875-82)

Changes in Hospitalization Patterns Among Patients With Congenital Heart Disease During the Transition From Adolescence to Adulthood




Seção Médica de Eletrofisiologia Clínica e Arritmias Cardíacas
Instituto Dante Pazzanese de Cardiologia



**Porcentagem das admissões no PS entre
2000 e 2003 na Califórnia**

(J Am Coll Cardiol 2007;49:875-82)

Causas de morte nas cardiopatias congênitas



The spectrum of adult congenital heart disease in Europe: morbidity and mortality in a 5 year follow-up period

The Euro Heart Survey on adult congenital heart disease

Table 2 History of morbidity and functional status at baseline

	Endocarditis	CVA/TIA	MI/CABG/PTCA	Supraventricular arrhythmias	Ventricular arrhythmias	NYHA I	NYHA II	NYHA III/IV
ASD II	0 (3/879)	4 (36/876)	2 (16/880)	28 (243/861)	2 (16/861)	59 (504/825)	30 (257)	11 (91)
VSD	7 (44/621)	2 (14/622)	1 (5/626)	9 (56/617)	3 (18/617)	76 (472/619)	19 (118)	4 (29)
Tetralogy of Fallot	4 (33/810)	4 (32/807)	1 (5/806)	20 (159/796)	14 (115/796)	69 (551/793)	24 (189)	6 (53)
CoA	2 (11/547)	1 (6/545)	1 (4/546)	4 (21/547)	2 (9/547)	81 (441/543)	15 (84)	3 (18)
Transposition	1 (4/361)	6 (20/359)	0 (1/360)	26 (95/362)	2 (7/362)	67 (244/362)	27 (96)	6 (22)
Marfan syndrome	2 (5/284)	1 (4/285)	1 (2/286)	8 (23/281)	2 (6/281)	79 (223/282)	19 (54)	2 (5)
Fontan circulation	2 (3/198)	12 (23/198)	0 (0/198)	45 (90/198)	0 (0/198)	40 (78/193)	51 (98)	9 (17)
Cyanotic defect	6 (22/386)	10 (37/384)	0 (1/385)	16 (58/374)	6 (22/374)	12 (45/172)	44 (172)	44 (170)
Overall	3 (125/4086)	4 (172/4076)	1 (34/4088)	18 (745/4036)	5 (193/4036)	63 (2558/4031)	26 (1068)	10 (405)

All values are percentage followed by a fraction with frequency in the numerator and the number of patients with sufficient data to evaluate the item (k/n) in the denominator. In the last two columns only the numerators are given, as the rows of the last three columns sum to 100%.

CVA, cerebrovascular accident; TIA, transient ischaemic attack; MI, myocardial infarction; CABG, coronary artery bypass graft; PTCA, percutaneous transluminal coronary angioplasty; NYHA, New York Heart Association functional class.



European Heart Journal (2005) 26, 2325–2333
doi:10.1093/eurheartj/ehi396

The spectrum of adult congenital heart disease in Europe: morbidity and mortality in a 5 year follow-up period

The Euro Heart Survey on adult congenital heart disease

Table 2 History of morbidity and functional status at baseline

	Endocarditis	CVA/TIA	MI/CABG/PTCA	Supraventricular arrhythmias	Ventricular arrhythmias	NYHA I	NYHA II	NYHA III/IV
ASD II	0 (3/879)	4 (36/876)	2 (16/880)	28 (243/861)	2 (16/861)	59 (504/825)	30 (257)	11 (91)
VSD	7 (44/621)	2 (14/622)	1 (5/626)	9 (56/617)	3 (18/617)	76 (472/619)	19 (118)	4 (29)
Tetralogy of Fallot	4 (33/810)	4 (32/807)	1 (5/806)	20 (159/796)	14 (115/796)	69 (551/793)	24 (189)	6 (53)
CoA	2 (11/547)	1 (6/545)	1 (4/546)	4 (21/547)	2 (9/547)	81 (441/543)	15 (84)	3 (18)
Transposition	1 (4/361)	6 (20/359)	0 (1/360)	26 (95/362)	2 (7/362)	67 (244/362)	27 (96)	6 (22)
Marfan syndrome	2 (5/284)	1 (4/285)	1 (2/286)	8 (23/281)	2 (6/281)	79 (223/282)	19 (54)	2 (5)
Fontan circulation	2 (3/198)	12 (23/198)	0 (0/198)	45 (90/198)	0 (0/198)	40 (78/193)	51 (98)	9 (17)
Cyanotic defect	6 (22/386)	10 (37/384)	0 (1/385)	16 (58/374)	6 (22/374)	12 (45/172)	44 (172)	44 (170)
Overall	3 (125/4086)	4 (172/4076)	1 (34/4088)	18 (745/4036)	5 (193/4036)	63 (2558/4031)	26 (1068)	10 (405)

All values are percentage followed by a fraction with frequency in the numerator and the number of patients with sufficient data to evaluate the item (k/n) in the denominator. In the last two columns only the numerators are given, as the rows of the last three columns sum to 100%.

CVA, cerebrovascular accident; TIA, transient ischaemic attack; MI, myocardial infarction; CABG, coronary artery bypass graft; PTCA, percutaneous transluminal coronary angioplasty; NYHA, New York Heart Association functional class.

OOKA, LEONARDO KIYOSHI
319731
Age:31 years
M
27 Sep 2012
14:49:03


INSTITUTO DANTE PAZZANESE
Ref:ANDERSON ROSA PEREIRA
CT
CORACAO
SEGMENT 75% 0.00s Cardiac 0.5 CE 75%



Seção Médica de Eletrofisiologia Clínica e Arritmias Cardíacas
Instituto Dante Pazzanese de Cardiologia

OOKA, LEONARDO KIYOSHI
319731
Age:31 years
M
27 Sep 2012
14:49:03

INSTITUTO DANTE PAZZANESE
Ref:ANDERSON ROSA PEREIRA
CT
CORACAO
SEGMENT 75% 0.00s Cardiac 0.5 CE 75%




kVP:120
mA:400
msec:400
mAs:102
Thk:0.5 mm
Aquilion
Orient: 39°,12°,26°

Vitrea®
Phase %75
W/L:271/223
Segmented



Seção Médica de Eletrofisiologia Clínica e Arritmias Cardíacas
Instituto Dante Pazzanese de Cardiologia








Seção Médica de Eletrofisiologia Clínica e Arritmias Cardíacas
Instituto Dante Pazzanese de Cardiologia




European Heart Journal (2009) 30, 1873–1879

CLINICAL RESEARCH



Perda da Função Ventrículo sistêmico (VD) Senning/ Mustard



Doka
Eduardo
Assessor da Funcao AV
319/31
Stor, Elavision
06.05.1251

10.10.2012
09:10:23
27° LAC
0°
33-☀
33-☾


87 kVp
3,70 mA

1.1 mir
17,39 mGy/mir
48,61 mGy

Ao vivo


OEC







ID: 04-05-22
S/N:
DdN: mmHg ...cm ...kg

Leonardo Higashide



10mm/mV 25mm/s $\approx$ Auto





Sem Nome 045

1 (F1/4) Sem Nome 045

INSTITUTO DANTE PAZZANES

25.06.2013 16:31:39

16:31:39

PSem06251631

21°
0°

LAO



Cateter
Decapolar
(VCS)

Cateter 8 mm
(aorta)

ETE

Cateter 4 mm
(VCI)



1C

C32767

W65535

Not for diagnostic use

OEC



GE_HEALTHCARE


Sem Nome 045
1 (F1/4)

INSTITUTO DANTE PAZZANZI
25/06/2013 16:31:39

PSem06251631

21° LAO
0°

33
37



1C

C32767
W65535
Not for diagnostic use

OEC



GE HEALTHCARE




ARRHYTHMIAS IN ADULTS WITH CONGENITAL HEART DISEASE

John K Friedman


Heart 2002;87:383–389

*Mustard and
Senning
procedures*



Patients born with transposition of the great vessels in the 1970s through the early 1990s were palliated by the construction of intra-atrial baffles using either synthetic material (the Mustard procedure) or by folding and augmentation of the atrial wall (the Senning procedure). Both redirect caval and pulmonary venous blood to correct cyanosis, utilising the right ventricle as the systemic ventricle. These operations have largely been abandoned in favour of the arterial switch procedure.

*Fontan
procedures*



Many congenital heart defects have in common anatomical features that preclude surgical septation of the ventricles resulting in univentricular physiology. The common end point of staged surgical palliation is the Fontan procedure, which utilises the single ventricle as the systemic ventricle and sends blood directly from the systemic veins to the pulmonary arteries. Several approaches to this have been used; currently, an anastomosis between the superior vena cava and pulmonary artery is created, with an intercaval connection effected by tube graft or intra-atrial baffle.

*Repaired
Tetralogy of
Fallot (TOF)*



The prevalence of TOF, its potential for survival through childhood without operation, and the early date at which reparative surgery became available have resulted in large group of patients with relatively homogenous clinical experience. Repair involves closure of the ventricular septal defect (VSD) and relief of right ventricular obstruction, often requiring both ventriculotomy and atriotomy.

Figure 1 Congenital heart malformations commonly associated with arrhythmia.

D-Transposition of the Great Arteries




The Current Era of the Arterial Switch Operation

Juan Villafañe, MD,* M. Regina Lantin-Hernando, MD,† Ami B. Bhatt, MD,‡ James S. Tweddell, MD,§
Tal Geva, MD,|| Meena Nathan, MD,¶ Martin J. Elliott, MD,# Victoria L. Vetter, MD, MPH,**
Stephen M. Paridon, MD,†† Lazaros Kochilas, MD, MSCR,‡‡ Kathy J. Jenkins, MD, MPH,§§
Robert H. Beekman III, MD,||| Gil Wernovsky, MD,¶¶ Jeffrey A. Towbin, MD,## on behalf of the
American College of Cardiology's Adult Congenital and Pediatric Cardiology Council

PO tardio



**Rastreamento
ativo**



D-Transposition of the Great Arteries




The Current Era of the Arterial Switch Operation

Juan Villafañe, MD,* M. Regina Lantin-Hernoso, MD,† Ami B. Bhatt, MD,‡ James S. Tweddell, MD,§
Tal Geva, MD,|| Meena Nathan, MD,¶ Martin J. Elliott, MD,# Victoria L. Vetter, MD, MPH,**
Stephen M. Paridon, MD,†† Lazaros Kochilas, MD, MSCR,‡‡ Kathy J. Jenkins, MD, MPH,§§
Robert H. Beekman III, MD,||| Gil Wernovsky, MD,¶¶ Jeffrey A. Towbin, MD,## on behalf of the
American College of Cardiology's Adult Congenital and Pediatric Cardiology Council

JACC VOL. 64, NO. 5, 2014


AUGUST 5, 2014:498-511



Cardiac Outcomes in Young Adult Survivors of the Arterial Switch Operation for Transposition of the Great Arteries

Daniel Tobler, MD,* William G. Williams, MD,† Anusha Jegatheeswaran, MD,† Glen S. Van Arsdell, MD,† Brian W. McCrindle, MD,† Matthias Greutmann, MD,* Erwin N. Oechslin, MD,* Candice K. Silversides, MD*
Toronto, Ontario, Canada

Sobrevivência entre 132 pacientes com Jatene operados na infância



(J Am Coll Cardiol 2010;56:58–64)

D-Transposition of the Great Arteries



The Current Era of the Arterial Switch Operation

Juan Villafañe, MD,* M. Regina Lantin-Hermoso, MD,† Ami B. Bhatt, MD,‡ James S. Tweddell, MD,§
Tal Geva, MD,|| Meena Nathan, MD,¶ Martin J. Elliott, MD,# Victoria L. Vetter, MD, MPH,**
Stephen M. Paridon, MD,†† Lazaros Kochilas, MD, MSCR,‡‡ Kathy J. Jenkins, MD, MPH,§§
Robert H. Beekman III, MD,||| Gil Wernovsky, MD,¶¶ Jeffrey A. Towbin, MD,## on behalf of the
American College of Cardiology's Adult Congenital and Pediatric Cardiology Council

TABLE 3 Post-Operative Sequelae Following the Arterial Switch Operation

Long-Term Post-Operative Sequelae	Incidence
Supravalvular pulmonary stenosis*	~10%
Supravalvular aortic stenosis*	~5%
Neo-aortic root dilation	Nearly universal
Neo-aortic regurgitation	Most (moderate or severe in <10%)
Asymptomatic coronary occlusion	2%-7%
Sudden cardiac death	<1%
Arrhythmia	2%-10%
Aortic dissection or rupture	Unknown
*Requiring intervention. Modified with permission from Wernovsky et al. (152).	

D-Transposition of the Great Arteries



The Current Era of the Arterial Switch Operation

Juan Villafañe, MD,* M. Regina Lantin-Hermoso, MD,† Ami B. Bhatt, MD,‡ James S. Tweddell, MD,§
Tal Geva, MD,|| Meena Nathan, MD,¶ Martin J. Elliott, MD,# Victoria L. Vetter, MD, MPH,**
Stephen M. Paridon, MD,†† Lazaros Kochilas, MD, MSCR,‡‡ Kathy J. Jenkins, MD, MPH,§§
Robert H. Beekman III, MD,||| Gil Wernovsky, MD,¶¶ Jeffrey A. Towbin, MD,## on behalf of the
American College of Cardiology's Adult Congenital and Pediatric Cardiology Council

TABLE 3 Post-Operative Sequelae Following the Arterial Switch Operation

Long-Term Post-Operative Sequelae	Incidence
Supravalvular pulmonary stenosis*	~10%
Supravalvular aortic stenosis*	~5%
Neo-aortic root dilation	Nearly universal
Neo-aortic regurgitation	Most (moderate or severe in <10%)
Asymptomatic coronary occlusion	2%-7%
Sudden cardiac death	<1%
Arrhythmia	2%-10%
Aortic dissection or rupture	Unknown

*Requiring intervention. Modified with permission from Wernovsky et al. (152).



Coronary Artery Problems Late After Arterial Switch Operation for Transposition of the Great Arteries

Takeshi Tsuda, MD; Abdul M. Bhat, MD; Bradley W. Robinson, MD;
Jeanne M. Baffa, MD; Wolfgang Radtke, MD

(*Circ J* 2015; 79: 2372–2379)

Table 2. Indications for Coronary Investigation

Indications	n=40	%
Investigation of abnormal hemodynamics on echocardiogram	24	60.0
Routine assessment (sports clearance)	7	17.5
Symptoms	4	10.0
Chest pain	1	
Palpitations (patient 5)	1	
Sudden death-autopsy* (patient 1)	1	
Cardiac arrest/VF* (patient 2)	1	
Unusual coronary anatomy	2	5.0
Abnormal EST or MPI (patients 4, 6)	2	5.0
ASD closure	1	2.5

ASD, atrial septal defect; VF, ventricular fibrillation. *Asymptomatic at outpatient visits. Other abbreviations as in Table 1.



Coronary Artery Problems Late After Arterial Switch Operation for Transposition of the Great Arteries

Takeshi Tsuda, MD; Abdul M. Bhat, MD; Bradley W. Robinson, MD;
Jeanne M. Baffa, MD; Wolfgang Radtke, MD

Table 2. Indications for Coronary Investigation

Indications	n=40	%
Investigation of abnormal hemodynamics on echocardiogram	24	60.0
Routine assessment (sports clearance)	7	17.5
Symptoms	4	10.0
Chest pain	1	
Palpitations (patient 5)	1	
Sudden death-autopsy* (patient 1)	1	
Cardiac arrest/VF* (patient 2)	1	
Unusual coronary anatomy	2	5.0
Abnormal EST or MPI (patients 4, 6)	2	5.0
ASD closure	1	2.5

(*Circ J* 2015; 79: 2372–2379)

ASD, atrial septal defect; VF, ventricular fibrillation. *Asymptomatic at outpatient visits. Other abbreviations as in Table 1.

Presença de alterações ECG em anormalidades de coronárias

Table 4. Test Results and Outcome of Significant Coronary Abnormalities (n=7)

Patient ID no.	ECG	Echocardiogram	EST	MPI	MRI	Outcome
1	NSR, WNL	Normal RV, LV function; Branch PA not well visualized	ND	ND	Slight narrowing of RPA; Coronary not delineated (3.25 years)	Sudden death (3.75 years)
2	NSR, WNL	Mild RV enlargement, Moderate neo-PI; Mild neo-Ao dilatation	Normal	Normal	ND	Alive
3	NSR, RBBB	Mild RV enlargement, mild branch PA stenosis, mild-moderate neo PI	Normal	Normal	Significant narrowing of LCA orifice	Alive
4	NSR, RBBB	Trivial supralvalvar neo-PS	Max $\dot{V}O_2$ 65% predicted ST-T depression (7 mm) in lateral leads	Reversible perfusion defect	ND	Alive
5	NSR, 1°AVB; Isolated PVC	Mild-moderate neo-AI	Max $\dot{V}O_2$ 72% predicted isolated PVC suppressed by exercise	Normal	Mild dilatation of neo-Ao, mild biventricular dilatation, LCA not well seen	Alive
6	NSR, RVH	Mild MPA stenosis, mild neo-AI	ND	ND	ND	Lost to follow-up
7	NSR, IRBBB	Free neo-PI (s/p transannular patch augmentation of RVOT at 3 months)	ST-T depression (2 mm) in lateral leads	Normal	Moderate RV dilation, mild proximal RPA narrowing, delayed Gd enhancement of LV endocardium	Alive

Myocardial Perfusion and Exercise Capacity 12 Years After Arterial Switch Surgery for D-Transposition of the Great Arteries

Table 3 Peak exercise test data

Variables	SWITCH	CON	<i>p</i> Value
Exercise time (min)	12.2 ± 1.9	14.1 ± 2.6	0.003
Peak heart rate (bpm)	188 ± 10	193 ± 10.2	0.01
% of age-predicted maximal HR obtained	94 ± 5	97 ± 5	0.007
Peak VO ₂ (ml/kg/min)	37.2 ± 8.2	42.5 ± 8.9	0.006
Peak VO ₂ /BMI (ml/min/[kg/m ²])	87.8 ± 31.0	110.1 ± 35.9	0.003
Oxygen pulse/BSA (ml/m ² /min)	6.56 ± 1.89	8.09 ± 3.19	0.009
O ₂ saturation at peak exercise	97 ± 3	97 ± 2	0.96

Note: SWITCH arterial switch operation, CON control, bpm beats per minute; BSA body surface area

Myocardial Perfusion and Exercise Capacity 12 Years After Arterial Switch Surgery for D-Transposition of the Great Arteries

Table 3 Peak exercise test data

Variables	SWITCH	CON	<i>p</i> Value
Exercise time (min)	12.2 ± 1.9	14.1 ± 2.6	0.003
Peak heart rate (bpm)	188 ± 10	193 ± 10.2	0.01
% of age-predicted maximal HR obtained	94 ± 5	97 ± 5	0.007
Peak VO ₂ (ml/kg/min)	37.2 ± 8.2	42.5 ± 8.9	0.006
Peak VO ₂ /BSA (ml/min/[kg/m ²])	87.8 ± 31.0	110.1 ± 35.9	0.003
Oxygen pulse/BSA (ml/m ² /min)	6.56 ± 1.89	8.09 ± 3.19	0.009
O ₂ saturation at peak exercise	97 ± 3	97 ± 2	0.96

Note: SWITCH arterial switch operation, CON control, bpm beats per minute; BSA body surface area


Cardiac Outcomes in Young Adult Survivors of the Arterial Switch Operation for Transposition of the Great Arteries

Daniel Tobler, MD,* William G. Williams, MD,† Anusha Jegatheeswaran, MD,† Glen S. Van Arsdel, MD,† Brian W. McCrindle, MD,† Matthias Greutmann, MD,* Erwin N. Oechslin, MD,* Candice K. Silversides, MD*

Toronto, Ontario, Canada

**Capacidade
aeróbica pacientes
com Jatene**

**Comparação de
necessidade de
reabordagem**



Cardiac Outcomes in Young Adult Survivors of the Arterial Switch Operation for Transposition of the Great Arteries

Daniel Tobler, MD,* William G. Williams, MD,† Anusha Jegatheeswaran, MD,† Glen S. Van Arsdell, MD,† Brian W. McCrindle, MD,† Matthias Greutmann, MD,* Erwin N. Oechslin, MD,* Candice K. Silversides, MD*
Toronto, Ontario, Canada

Table 3	Reinterventions in Adulthood After ASO				
Sex	Anatomy	ASO	Anastomosis	Reoperation in Childhood	Reoperation in Adulthood
F	Complex	1980	RV-PA conduit	None	Pulmonary arterioplasty, sternal wire removal
F	Complex	1980	RV-PA conduit	Conduit replacement	PVR, pulmonary arterioplasty, RVOT resection
F	Complex	1981	RV-PA conduit	Pulmonary arterioplasty	Coronary artery revision, conduit replacement
M	Complex	1986	RV-PA conduit	RVOT repair, pulmonary arterioplasty	Pacemaker replacement
F	Complex	1987	Lecompte	Mitral valve repair/replacement/PM	Mitral valve replacement
M	Complex	1989	Lecompte	Pulmonary arterioplasty	Pulmonary arterioplasty
M	Simple	1990	Lecompte	None	Pacemaker Implant

PM = pacemaker; PVR = pulmonary valve replacement; RVOT = right ventricular outflow tract; other abbreviations as in Table 1.

Outcomes of the Arterial Switch Operation for Transposition of the Great Arteries: 25 Years of Experience

Tyson A. Fricke, BMedSc, Yves d'Udekem, MD, PhD, Malcolm Richardson, MBBS, Clarke Thuys, BAppSc, Mithilesh Dronavalli, MBBS, BMedSc, James M. Ramsay, MBBS, Gavin Wheaton, MBBS, Leeanne E. Grigg, MBBS, Christian P. Brizard, MD, and Igor E. Konstantinov, MD, PhD

Royal Children's Hospital, Melbourne; University of Melbourne, Melbourne; Murdoch Children's Research Institute, Melbourne; Royal Melbourne Hospital, Melbourne; Women's and Children's Hospital, Adelaide; and Princess Margaret Hospital, Perth, Australia




Fig 1. Freedom from mortality. (AAO = aortic arch obstruction; ASO = arterial switch operation; IVS = intact ventricular septum; TGA = transposition of the great arteries; VSD = ventricular septal defect; — = TGA-IVS; - - - = TGA-VSD; -.-.- = TGA-AAO.)

Declining Aerobic Capacity of Patients with Arterial and Atrial Switch Procedures

Per Morten Fredriksen · Eirik Pettersen ·
Erik Thaulow

Table 4 Mean data from exercise tests for patients with atrial and arterial corrected transposition of the great arteries compared with healthy subjects

	Atrial	Arterial	Healthy ^a	<i>p</i> -value ^b
Percentage of healthy reference	69 ± 15.4	80 ± 16.5		0.002
VO _{2peak} (ml kg ^{-0.67} min ⁻¹)	132 ± 27.8	145 ± 32.5	182 ± 31.3 ^c	0.060
VO _{2peak} (ml kg ⁻¹ min ⁻¹)	36.9 ± 8.92	43.1 ± 9.65	53.1 ± 7.82 ^c	0.003
VO _{2peak} (l min ⁻¹)	1.776 ± 0.427	1.757 ± 0.579	2.315 ± 0.709 ^c	0.859
HR _{peak} (bpm)	182 ± 9	190 ± 13	200 ± 7 ^c	0.004
VE _{peak} (l min ⁻¹)	70.5 ± 19.0	70.6 ± 20.4	82.1 ± 23.9 ^c	0.990
Respiratory exchange ratio	1.05 ± 0.07	1.01 ± 0.08	1.10 ± 0.06 ^c	0.030

^a Healthy Norwegian reference material is from Fredriksen et al. (1999) [2]. The reference results are the mean values


^b The *p* value refers to the difference between the atrial and arterial surgery groups

^c Significant difference between the results of the reference population and both TGA groups

Declining Aerobic Capacity of Patients with Arterial and Atrial Switch Procedures


Per Morten Fredriksen · Eirik Pettersen ·
Erik Thaulow

**Comparação da
capacidade
funcional
Senning vs Jatene**



Cardiovascular Outcomes After the Arterial Switch Operation for D-Transposition of the Great Arteries


Paul Khairy, MD, PhD; Mathieu Clair, MD; Susan M. Fernandes, MHP, PA-C;
Elizabeth D. Blume, MD; Andrew J. Powell, MD; Jane W. Newburger, MD, MPH;
Michael J. Landzberg, MD; John E. Mayer Jr, MD



(*Circulation*. 2013;127:331–339.)

Cardiovascular Outcomes After the Arterial Switch Operation for D-Transposition of the Great Arteries

Paul Khairy, MD, PhD; Mathieu Clair, MD; Susan M. Fernandes, MHP, PA-C;
Elizabeth D. Blume, MD; Andrew J. Powell, MD; Jane W. Newburger, MD, MPH;
Michael J. Landzberg, MD; John E. Mayer Jr, MD




(*Circulation*. 2013;127:331–339.)


Cardiovascular Outcomes After the Arterial Switch Operation for D-Transposition of the Great Arteries

Paul Khairy, MD, PhD; Mathieu Clair, MD; Susan M. Fernandes, MHP, PA-C;
Elizabeth D. Blume, MD; Andrew J. Powell, MD; Jane W. Newburger, MD, MPH;
Michael J. Landzberg, MD; John E. Mayer Jr, MD

Liberdade de eventos cardiovasculares



Liberdade de Morte Súbita



(*Circulation*. 2013;127:331–339.)

Original article

Characteristics and Outcomes of Transposition of Great Arteries in the Neonatal Period


Anna Turon-Viñas,^a Ana Riverola-de Veciana,^{a,*} Julio Moreno-Hernando,^a Joaquim Bartrons-Casas,^b Fredy H. Prada-Martínez,^b Javier Mayol-Gómez,^c and José M. Caffarena-Calvar^c

Morbidity

Laboratory tests suggested infection in 22 of 117 patients [18.8%]. Sepsis was confirmed by positive blood culture (12 of 117 [10.2%]) and urinary tract infection by positive urine culture (4 of 117 [3.4%]). Arrhythmias occurred in 22 patients during the immediate postoperative period. Two patients required pacemaker implantation and 6 needed medical treatment; the arrhythmia resolved spontaneously in the remaining patients. The most common pulmonary complication was pulmonary edema, with or without pleural effusion (20 cases [17%]). There were 9 cases of diaphragmatic paralysis.

Pharmacological and non-pharmacological therapy for arrhythmias in the pediatric population: EHRA and AEPC-Arrhythmia Working Group joint consensus statement

Risco de eventos arrítmicos na TGA



**Busca ativa de eventos arrítmicos
que possam aumentar a
mortalidade!!!**

Remote Monitoring Leads to Early Recognition and Treatment of Critical Arrhythmias in Adults After Atrial Switch Operation for Transposition of the Great Arteries

Bert Nagel, MD; Jan Janousek, PhD; Martin Koestenberger, PhD; Robert Maier, MD; Werner Sauseng, MD; Volker Strenger, PhD; Andreas Gamillscheg, PhD; Peter Zartner, MD

Table 1. Patient Data at Enrollment

Patient	Age (years)	Type of repair	Follow-up (years)	Device†	Indication	RVEF (%) / TAPSE (mm)	NYHA class	Arrhythmia before implant	Anti-arrhythmic medication
1	20.2	Mustard	3.3	Cylos DR-T	SSS, AVB	≥50/16	1	None	None
2	31.8	Senning	1.5	Evia DR-T	SSS	40–49/12	2	None	None
3	31.2	Mustard	1.1	Evia DR-T	SSS, AVB	40–49/15	1	None	None
4	21.4	Senning	2.1	Evia DR-T	SSS	30–39/10	2	AFI	β-blocker
5	19.7	Senning	2.1	Evia DR-T	SSS, AVB	30–39/11	2	AFI	β-blocker
6	22.9	Senning	1.9	Evia DR-T	SSS, AVB	30–39/10	2	None	None
7	25.2	Mustard	1.9	Lumax HF-T	SSS, AVB	<30/6	3	VT	β-blocker
8	31.7	Mustard	0.3	Lumax HF-T	SSS	30–39/9	2	None	None
9	25	Mustard	1.6	Stratos LV-T‡	SSS, AVB	<30/8	3	VEB>250/h	β-blocker
10	26.7	Mustard	1.8	Stratos LV-T	SSS, AVB	<30/8	3	VEB>100/h	β-blocker
11	18.8	Mustard	3.6	Stratos LV-T	SSS	30–39/9	2	VEB>250/h	β-blocker

†All devices by Biotronic, Berlin, Germany (patients 1–6, pacemaker; 7,8, CRT-D; 9–11, CRT); ‡epicardial CRT system, all other devices were implanted transvenously.

AFI, atrial flutter; AVB, higher degree atrioventricular block; CRT, cardiac resynchronization therapy without ICD; CRT-D, cardiac resynchronization therapy with ICD; ICD, implantable cardioverter defibrillator; NYHA, New York Heart Association; RVEF, right ventricular ejection fraction; SSS, sick sinus syndrome; TAPSE, tricuspid annular plane systolic excursion; VEB, ventricular ectopic beats; VT, non-sustained ventricular tachycardia.

Implante de CDI em pacientes com TGA

Profilaxia Primaria


TABLE I. Key Determinants of ICD Implantation in Adult TGA Patients for Primary Prevention of SCD

Factors Favoring ICD Implantation	Factors Opposing ICD Implantation
High degree of association between systemic ventricular dysfunction and SCD	Unestablished cause of SCD: tachyarrhythmias (i.e., supraventricular or ventricular), ventricular failure, or both
Established survival benefit in non-ACHD patients with ventricular failure	Lack of evidence-based survival benefit for primary-prevention ICD placement
Limited evidence supporting survival benefit in ACHD patients who have secondary implantation indications	High frequency of inappropriate shocks
Advancing ICD technology	Device-related complications (primarily lead fracture and failure)
	Poor defibrillation thresholds for implanted devices, due to altered anatomy


ACHD = adult congenital heart disease; ICD = implantable cardioverter-defibrillator; SCD = sudden cardiac death; TGA = transposition of the great arteries

(Tex Heart Inst J 2015;42(4):309-18)


Quantos dias em média levamos para iniciar a investigação



ECG



Holter




Segundo Holter e Holter 7 dias





Telemetria ambulatorial




Monitor de eventos externo



Monitor eventos implantável





Resumo 7 dias

Nº do Exame
5859780

Paciente:

Data do Exame: _____


Código:
1J4-00017

Data	FC Mín.	FC Méd.	FC Máx.	V iso.	V par.	Total V	SV iso.	SV par.	Total SV	Pausas	> Pausa	% Artefato	> Depr. ST	Inclin. ST	Depr. Cn
25/01/2015	46	76	151	378	35	475	91	153	511	17	7,8	18 %			
26/01/2015	54	82	141	438	31	509	123	171	548	4	4,3	19 %			
27/01/2015	52	81	145	108	10	128	37	61	182	2	3,2	6 %			
28/01/2015	49	82	144	84	5	94	45	48	238	9	4,7	2 %			
29/01/2015	46	87	163	90	5	100	92	114	571	2	19,1	4 %			
30/01/2015	54	87	145	23	0	23	14	11	56	3	2,9	< 1 %			
31/01/2015	53	85	144	15	1	17	10	11	129	0		< 1 %			
Total	46	83	163	1136	87	1346	412	569	2235	37	19	7 %			

Data	Taq. V	TV maior	TV mais rápida	TV mais lenta	aq. S	TSV maior	TSV mais rápida	TSV mais lenta
25/01/2015	8	5 bat., 125 bpm 05:25:28	3 bat., 180 bpm 02:45:50	4 bat., 92 bpm 04:18:14	24	13 bat., 124 bpm 16:38:02	3 bat., 216 bpm 09:01:37	5 bat., 88 bpm 17:10:44
26/01/2015	3	3 bat., 233 bpm 21:40:02	3 bat., 233 bpm 21:40:02	3 bat., 123 bpm 04:35:40	21	8 bat., 97 bpm 17:34:13	3 bat., 250 bpm 18:38:11	4 bat., 94 bpm 15:43:03
27/01/2015	0				3	15 bat., 93 bpm 12:51:40	3 bat., 233 bpm 16:30:07	5 bat., 90 bpm 12:52:20
28/01/2015	0				17	16 bat., 91 bpm 12:29:01	4 bat., 205 bpm 22:55:55	10 bat., 90 bpm 12:37:21
29/01/2015	0				38	18 bat., 91 bpm 17:53:12	4 bat., 188 bpm 02:11:33	6 bat., 87 bpm 13:47:38
30/01/2015	0				3	14 bat., 102 bpm 16:59:40	3 bat., 159 bpm 06:01:12	14 bat., 102 bpm 16:59:40
31/01/2015	0				7	35 bat., 94 bpm 16:32:14	3 bat., 150 bpm 10:29:24	9 bat., 93 bpm 07:26:06
Total	11	5 bat., 125 bpm 05:25:28	3 bat., 233 bpm 21:40:02	4 bat., 92 bpm 04:18:14	113	35 bat., 94 bpm 16:32:14	3 bat., 250 bpm 18:38:11	6 bat., 87 bpm 13:47:38


Looper com transmissão via internet

BOTÃO DE EVENTOS



VERMELHO (RA)	Apêndice Xifóide (V1-2)
AMARELO (LA)	Quinto espaço intercostal esquerdo (V5)
PRETO (RL)	Manúbrio Esternal (M)

Looper com transmissão via internet




ACIONAMENTO DO
BOTÃO DE EVENTOS

REGISTROS ALEATÓRIOS
COM TEMPO
PROGRAMÁVEL

Incremento diagnóstico com o prolongamento da monitorização

% dos pacientes com FA detectada



Atrial Fibrillation in Patients with Cryptogenic Stroke

David J. Gladstone, M.D., Ph.D., Melanie Spring, M.D., Paul Dorian, M.D., Val Panzov, M.D., Kevin E. Thorpe, M.Math., Judith Hall, M.Sc., Haris Vaid, B.Sc., Martin O'Donnell, M.B., Ph.D., Andreas Laupacis, M.D., Robert Côté, M.D., Mukul Sharma, M.D., John A. Blakely, M.D., Ashfaq Shuaib, M.D., Vladimir Hachinski, M.D., D.Sc., Shelagh B. Coutts, M.B., Ch.B., M.D., Demetrios J. Sahlas, M.D., Phil Teal, M.D., Samuel Yip, M.D., J. David Spence, M.D., Brian Buck, M.D., Steve Verreault, M.D., Leanne K. Casaubon, M.D., Andrew Penn, M.D., Daniel Selchen, M.D., Albert Jin, M.D., David Howse, M.D., Manu Mehdiratta, M.D., Karl Boyle, M.B., B.Ch., Richard Aviv, M.B., Ch.B., Moira K. Kapral, M.D., and Muhammad Mamdani, Pharm.D., M.P.H., for the EMBRACE Investigators and Coordinators*



Sobre o monitor implantável



Reveal
1998

Avaliação de síncope



Reveal Plus
2000

Automatização



Reveal DX
2007

Maior Bateria (3 anos) Maior capacidade de memória
(50 minutos) log para taquicardia e CDI
Acesso remoto e uso em RNM





Reveal XT
2009



Deteccção de FA
Compasso





Como se apresentam os Ritmos no monitor de eventos implantável



Fib Atrial




Flutter Atrial
3:1



Ritmo Sinusal



**Seção Médica de Eletrofisiologia Clínica e Arritmias Cardíacas
Instituto Dante Pazzanese de Cardiologia**





**American
Heart
Association®**

life is why™



Seção Médica de Eletrofisiologia Clínica e Arritmias Cardíacas
Instituto Dante Pazzanese de Cardiologia

Equipe de Eletrofisiologia Pediátrica

Obrigado!!!

rogerioandalaft@arritmiaonline.com.br

rogerio.andala@einstein.br

Download em

www.arritmiaonline.com.br

